98%
921
2 minutes
20
Purpose: The purpose of this study was to determine whether temporal subtraction (TS) computed tomography (CT) contributes to the detection of vertebral bone metastases.
Method: The calculation of TS CT was composed of bony landmark detection, bone segmentation with a multiatlas-based method, and spatial registration. Temporal increase and decrease of the CT values were visualized in blue and red, respectively. Paired CT images of 20 patients with cancer and newly-developed vertebral metastases were analyzed. Control CT examinations of 20 different patients were also included. The presence of vertebral metastases on the TS CT was evaluated by two board-certified radiologists. Five additional board-certified radiologists and five radiology residents independently interpreted the 40 paired CT images with and without TS CT.
Results: In the lesion conspicuity evaluation, 96% of vertebral metastases were scored as excellent or good. In the image interpretation examination, according to free-response receiver operating characteristics analysis, the overall figure of merit (FOM) of the board-certified radiologist group was 0.892 and 0.898 with and without TS CT, respectively. The FOM of the resident group improved from 0.849 to 0.902 with viewing TS CT. In the sub-analysis focusing on the location of the lesion, the FOM of the resident group significantly improved from 0.75 to 0.92 in vertebral arch lesions (p = 0.001).
Conclusions: The TS CT may be useful to detect vertebral metastases because almost all the vertebral metastases were shown to be favorable visualization. The TS CT was proven to be especially helpful for radiology residents in detecting vertebral arch metastases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejrad.2019.07.024 | DOI Listing |
Palliat Med Rep
April 2025
Department of Oncology, King Faisal Specialist Hospital & Research Centre (KFSH&RC), Jeddah, Saudi Arabia.
Background And Aims: Palliative radiotherapy practice patterns have been reported to vary widely, with a notable underutilization of single fraction treatment schedules. This study aims to investigate the outcomes and care patterns among patients receiving palliative radiotherapy for advanced cancer at a high-volume institution in Saudi Arabia.
Materials And Methods: Electronic records were used to identify patients receiving palliative radiotherapy for advanced cancer between 2018 and 2023.
Front Endocrinol (Lausanne)
September 2025
Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Paragangliomas (PGLs) are rare neuroendocrine tumors originating from the extra-adrenal autonomic paraganglia with a strong genetic background. pathogenic variants are associated with the highest rate of malignancy in PGLs. Most head and neck paragangliomas (HNPGs) are asymptomatic and benign, and multiple metastases are rare.
View Article and Find Full Text PDFNeuropathology
October 2025
Pathology Department, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Glioblastoma (GB), IDH-wildtype (IDH-wt), is the most prevalent primary malignant brain neoplasm in adults. Despite adjuvant therapy, the prognosis for these tumors remains dismal, with a median survival of around 15-18 months. Although rare, extracranial metastases from GB are reported with increasing frequency, likely due to advancements in follow-up, treatments, and improved patient survival.
View Article and Find Full Text PDFSkeletal Radiol
September 2025
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht & Utrecht University, PO Box 85500, 3508 GA, Utrecht, the Netherlands.
Objectives: To evaluate whether dual-layer spectral computed tomography, compared with conventional CT, improves diagnostic accuracy for osteolytic vertebral metastases. Furthermore, to investigate the influence of dual-layer CT on the subjective visibility of metastases.
Materials And Methods: In this single-center retrospective study, consecutive patients with an untreated primary tumor who underwent dual-layer CT and either MRI or PET-CT as reference standard within 14 days were included.
Pract Radiat Oncol
September 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Re-irradiation of spinal metastases using stereotactic body radiotherapy (SBRT) presents clinical challenges, with limited patient outcomes data to guide decision-making. We report a retrospective, single-institutional experience of 107 lesions treated in 91 patients. 88 (72%) lesions were initially irradiated with conventional radiotherapy (median equivalent dose of 33Gy to the target, interquartile range, IQR: 23-35 Gy) with a median time to re-irradiation of 12 months (IQR: 4-21 months).
View Article and Find Full Text PDF